- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT05564403
Изучение химиотерапии с биниметинибом или без него при распространенном раке желчевыводящих путей в условиях 2-й линии (испытание лечения ComboMATCH)
Испытание лечения ComboMATCH: FOLFOX в комбинации с биниметинибом в качестве терапии 2-й линии для пациентов с распространенным раком желчных путей с изменениями пути MAPK
This phase II ComboMATCH treatment trial compares the usual treatment of modified leucovorin, fluorouracil and oxaliplatin (mFOLFOX6) chemotherapy to using binimetinib plus mFOLFOX6 chemotherapy to shrink tumors in patients with biliary tract cancers that have spread to other places in the body (advanced) and had progression of cancer after previous treatments (2nd line setting). Fluorouracil is in a class of medications called antimetabolites. It works by slowing or stopping the growth of cancer cells in the body. Oxaliplatin is in a class of medications called platinum-containing antineoplastic agents. It works by killing tumor cells. Leucovorin may help the other drugs in the mFOLFOX6 chemotherapy regimen work better by making tumor cells more sensitive to the drugs. Binimetinib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals tumor cells to multiply. This helps to stop or slow the spread of tumor cells. Giving binimetinib in combination with mFOLFOX6 chemotherapy may be effective in shrinking or stabilizing advanced biliary tract cancers in the 2nd line setting.
Обзор исследования
Статус
Условия
- Внутрипеченочная холангиокарцинома III стадии AJCC v8
- Рак желчного пузыря III стадии AJCC v8
- Рецидивирующая карцинома желчного пузыря
- Неоперабельная карцинома желчного пузыря
- III стадия прикорневой холангиокарциномы AJCC v8
- Стадия IV Рак желчного пузыря AJCC v8
- Холангиокарцинома ворот ворот IV стадии AJCC v8
- Внутрипеченочная холангиокарцинома IV стадии AJCC v8
- Стадия IV рака дистального желчного протока AJCC v8
- Неоперабельная внутрипеченочная холангиокарцинома
- Прогрессирующая карцинома желчевыводящих путей
- Продвинутая внутрипеченочная холангиокарцинома
- Рецидивирующая внутрипеченочная холангиокарцинома
- Рак дистального желчного протока III стадии AJCC v8
- Прогрессирующая карцинома желчного пузыря
- Рецидивирующая карцинома желчных путей
- Неоперабельная карцинома желчевыводящих путей
Вмешательство/лечение
- Лекарство: Fluorouracil
- Процедура: Computed Tomography
- Процедура: Magnetic Resonance Imaging
- Процедура: Echocardiography Test
- Процедура: Multigated Acquisition Scan
- Процедура: Biopsy Procedure
- Процедура: Biospecimen Collection
- Лекарство: Binimetinib
- Лекарство: Leucovorin Calcium
- Лекарство: Oxaliplatin
- Процедура: Bone Scan
Подробное описание
PRIMARY OBJECTIVE:
I. To determine whether binimetinib and mFOLFOX6 combination therapy improves overall survival (OS) compared to mFOLFOX6 alone in patients with advanced/recurrent biliary tract cancer (BTC) and with alterations in RAS/RAF/MEK/ERK pathway, who have progressed on one prior line of therapy.
SECONDARY OBJECTIVES:
I. To determine whether binimetinib and mFOLFOX6 combination therapy improves objective response rate (ORR) compared to FOLFOX alone.
II. To determine if clinical outcomes including progression free survival (PFS), duration of response (DOR), and disease control rate (DCR) are improved with combination treatment of binimetinib and mFOLFOX6 compared to FOLFOX alone in patients with advanced/recurrent BTC and with alterations in RAS/RAF/MEK/ERK pathway who have progression on one prior line of therapy.
III. Toxicity and tolerability will be evaluated within and between the two treatment arms, where frequency, type, and severity of adverse events will be assessed per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version (v)5.0.
IV. Collect tissue and provide it to the ComboMATCH Registration Protocol to assess concordance between the diagnostic tumor mutation profile generated by the Designated Laboratories, the pre-treatment biopsy mutation profile, and the pre-treatment circulating tumor deoxyribonucleic acid (ctDNA) mutation profile from plasma, as described in ComboMATCH Registration Protocol.
EXPLORATORY OBJECTIVES:
I. Generate a prognostic model of MAPK mutations for this patient population using clinical, laboratory and molecular features of their disease and clinical outcome to validate on future samples.
II. Correlation of outcome with albumin. III. Assess the correlation between the presence of MAPK pathway mutations and activity of addition of binimetinib therapy to standard 2nd line chemotherapy.
IV. Conduct whole-exome sequencing and ribonucleic acid (RNA)-sequencing at baseline, and on optional biopsy upon progression to assess determinants of response and resistance.
V. Explore changes in plasma MAPK mutations allelic burden and other molecular findings at baseline and upon progression using ctDNA and correlate changes with clinical activity, disease course as well as response/resistance to therapy.
VI. Evaluate if our machine learning algorithm for RAS/RAF/MEK/ERK pathway mutations correlates with detection of mutations as well as prediction of outcomes from samples obtained in this study.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM 1: Patients receive leucovorin intravenously (IV) over 2 hours and oxaliplatin IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1-2. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients undergo collection of blood during screening and on study, and undergo computed tomography (CT) with contrast, magnetic resonance imaging (MRI), or fludeoxyglucose F-18 positron emission tomography (FDG-PET) throughout the trial as clinically indicated. Patients may also undergo bone scans on study and may undergo biopsies throughout the study as clinically indicated.
ARM 2: Patients receive binimetinib orally (PO) on days 1-14, and leucovorin IV, oxaliplatin IV, and fluorouracil IV as in Arm 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients undergo echocardiogram (ECHO) or multigated acquisition scan (MUGA) and collection of blood during screening and on study, and undergo CT with contrast, MRI, or FDG-PET throughout the trial as clinically indicated. Patients may also undergo bone scans on study and may undergo biopsies throughout the study as clinically indicated.
After completion of study treatment, patients are followed up every 8 weeks until disease progression, thereafter patients are followed for survival every 4 months for up to 5 years following registration.
Тип исследования
Регистрация (Действительный)
Фаза
- Фаза 2
Контакты и местонахождение
Места учебы
-
-
Alabama
-
Birmingham, Alabama, Соединенные Штаты, 35233
- University of Alabama at Birmingham Cancer Center
-
Mobile, Alabama, Соединенные Штаты, 36688
- University of South Alabama Mitchell Cancer Institute
-
-
Arizona
-
Phoenix, Arizona, Соединенные Штаты, 85054
- Mayo Clinic Hospital in Arizona
-
-
Arkansas
-
Jonesboro, Arkansas, Соединенные Штаты, 72401
- NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
-
-
California
-
La Jolla, California, Соединенные Штаты, 92093
- UC San Diego Moores Cancer Center
-
Los Angeles, California, Соединенные Штаты, 90048
- Cedars-Sinai Medical Center
-
Whittier, California, Соединенные Штаты, 90602
- Presbyterian Intercommunity Hospital
-
-
Florida
-
Aventura, Florida, Соединенные Штаты, 33180
- UM Sylvester Comprehensive Cancer Center at Aventura
-
Coral Gables, Florida, Соединенные Штаты, 33146
- UM Sylvester Comprehensive Cancer Center at Coral Gables
-
Deerfield Beach, Florida, Соединенные Штаты, 33442
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach
-
Gainesville, Florida, Соединенные Штаты, 32610
- UF Health Cancer Institute - Gainesville
-
Jacksonville, Florida, Соединенные Штаты, 32224-9980
- Mayo Clinic in Florida
-
Miami, Florida, Соединенные Штаты, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Miami, Florida, Соединенные Штаты, 33176
- UM Sylvester Comprehensive Cancer Center at Kendall
-
Plantation, Florida, Соединенные Штаты, 33324
- UM Sylvester Comprehensive Cancer Center at Plantation
-
-
Hawaii
-
Honolulu, Hawaii, Соединенные Штаты, 96813
- Queen's Medical Center
-
Honolulu, Hawaii, Соединенные Штаты, 96813
- Hawaii Cancer Care Inc - Waterfront Plaza
-
Honolulu, Hawaii, Соединенные Штаты, 96813
- Queen's Cancer Cenrer - POB I
-
Honolulu, Hawaii, Соединенные Штаты, 96817
- Queen's Cancer Center - Kuakini
-
‘Aiea, Hawaii, Соединенные Штаты, 96701
- Hawaii Cancer Care - Westridge
-
‘Ewa Beach, Hawaii, Соединенные Штаты, 96706
- The Queen's Medical Center - West Oahu
-
-
Idaho
-
Boise, Idaho, Соединенные Штаты, 83706
- Saint Alphonsus Cancer Care Center-Boise
-
Boise, Idaho, Соединенные Штаты, 83712
- Saint Luke's Cancer Institute - Boise
-
Caldwell, Idaho, Соединенные Штаты, 83605
- Saint Alphonsus Cancer Care Center-Caldwell
-
Coeur d'Alene, Idaho, Соединенные Штаты, 83814
- Kootenai Health - Coeur d'Alene
-
Fruitland, Idaho, Соединенные Штаты, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Соединенные Штаты, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Соединенные Штаты, 83687
- Saint Alphonsus Cancer Care Center-Nampa
-
Nampa, Idaho, Соединенные Штаты, 83687
- Saint Luke's Cancer Institute - Nampa
-
Post Falls, Idaho, Соединенные Штаты, 83854
- Kootenai Clinic Cancer Services - Post Falls
-
Sandpoint, Idaho, Соединенные Штаты, 83864
- Kootenai Clinic Cancer Services - Sandpoint
-
-
Illinois
-
Barrington, Illinois, Соединенные Штаты, 60010
- Advocate Good Shepherd Hospital
-
Chicago, Illinois, Соединенные Штаты, 60611
- Northwestern University
-
Chicago, Illinois, Соединенные Штаты, 60637
- University of Chicago Comprehensive Cancer Center
-
Chicago, Illinois, Соединенные Штаты, 60612
- John H Stroger Jr Hospital of Cook County
-
Chicago, Illinois, Соединенные Штаты, 60657
- Advocate Illinois Masonic Medical Center
-
Crystal Lake, Illinois, Соединенные Штаты, 60014
- AMG Crystal Lake - Oncology
-
Danville, Illinois, Соединенные Штаты, 61832
- Carle at The Riverfront
-
DeKalb, Illinois, Соединенные Штаты, 60115
- Northwestern Medicine Cancer Center Kishwaukee
-
Decatur, Illinois, Соединенные Штаты, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, Соединенные Штаты, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Downers Grove, Illinois, Соединенные Штаты, 60515
- Advocate Good Samaritan Hospital
-
Effingham, Illinois, Соединенные Штаты, 62401
- Crossroads Cancer Center
-
Effingham, Illinois, Соединенные Штаты, 62401
- Carle Physician Group-Effingham
-
Elgin, Illinois, Соединенные Штаты, 60123
- Advocate Sherman Hospital
-
Geneva, Illinois, Соединенные Штаты, 60134
- Northwestern Medicine Cancer Center Delnor
-
Glenview, Illinois, Соединенные Штаты, 60026
- Northwestern Medicine Glenview Outpatient Center
-
Grayslake, Illinois, Соединенные Штаты, 60030
- Northwestern Medicine Grayslake Outpatient Center
-
Hazel Crest, Illinois, Соединенные Штаты, 60429
- Advocate South Suburban Hospital
-
Lake Forest, Illinois, Соединенные Штаты, 60045
- Northwestern Medicine Lake Forest Hospital
-
Libertyville, Illinois, Соединенные Штаты, 60048
- Condell Memorial Hospital
-
Libertyville, Illinois, Соединенные Штаты, 60048
- AMG Libertyville - Oncology
-
Mattoon, Illinois, Соединенные Штаты, 61938
- Carle Physician Group-Mattoon/Charleston
-
New Lenox, Illinois, Соединенные Штаты, 60451
- UC Comprehensive Cancer Center at Silver Cross
-
O'Fallon, Illinois, Соединенные Штаты, 62269
- Cancer Care Center of O'Fallon
-
Oak Lawn, Illinois, Соединенные Штаты, 60453-2699
- Advocate Christ Medical Center
-
Orland Park, Illinois, Соединенные Штаты, 60462
- University of Chicago Medicine-Orland Park
-
Orland Park, Illinois, Соединенные Штаты, 60462
- Northwestern Medicine Orland Park
-
Park Ridge, Illinois, Соединенные Штаты, 60068
- Advocate Lutheran General Hospital
-
Shiloh, Illinois, Соединенные Штаты, 62269
- Memorial Hospital East
-
Springfield, Illinois, Соединенные Штаты, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Соединенные Штаты, 62702
- Springfield Clinic
-
Springfield, Illinois, Соединенные Штаты, 62781
- Springfield Memorial Hospital
-
Urbana, Illinois, Соединенные Штаты, 61801
- Carle Cancer Center
-
Warrenville, Illinois, Соединенные Штаты, 60555
- Northwestern Medicine Cancer Center Warrenville
-
-
Iowa
-
Ankeny, Iowa, Соединенные Штаты, 50023
- UI Health Care Mission Cancer and Blood - Ankeny Clinic
-
Des Moines, Iowa, Соединенные Штаты, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Waukee, Iowa, Соединенные Штаты, 50263
- UI Health Care Mission Cancer and Blood - Waukee Clinic
-
-
Kentucky
-
Lexington, Kentucky, Соединенные Штаты, 40536
- University of Kentucky/Markey Cancer Center
-
-
Maine
-
Brewer, Maine, Соединенные Штаты, 04412
- Lafayette Family Cancer Center-EMMC
-
-
Maryland
-
Baltimore, Maryland, Соединенные Штаты, 21201
- University of Maryland/Greenebaum Cancer Center
-
Bethesda, Maryland, Соединенные Штаты, 20892
- National Institutes of Health Clinical Center
-
Bethesda, Maryland, Соединенные Штаты, 20889-5600
- Walter Reed National Military Medical Center
-
Cumberland, Maryland, Соединенные Штаты, 21502
- UPMC Western Maryland
-
-
Michigan
-
Ann Arbor, Michigan, Соединенные Штаты, 48109
- University of Michigan Rogel Cancer Center
-
Ann Arbor, Michigan, Соединенные Штаты, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Brighton, Michigan, Соединенные Штаты, 48114
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Brighton, Michigan, Соединенные Штаты, 48116
- University of Michigan - Brighton Center for Specialty Care
-
Brighton, Michigan, Соединенные Штаты, 48114
- Trinity Health Medical Center - Brighton
-
Canton, Michigan, Соединенные Штаты, 48188
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Canton, Michigan, Соединенные Штаты, 48188
- Trinity Health Medical Center - Canton
-
Chelsea, Michigan, Соединенные Штаты, 48118
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Chelsea, Michigan, Соединенные Штаты, 48118
- Chelsea Hospital
-
Dearborn, Michigan, Соединенные Штаты, 48124
- Corewell Health Dearborn Hospital
-
Farmington Hills, Michigan, Соединенные Штаты, 48336
- Corewell Health Farmington Hills Hospital
-
Flint, Michigan, Соединенные Штаты, 48503
- Hurley Medical Center
-
Flint, Michigan, Соединенные Штаты, 48503
- Genesee Hematology Oncology PC
-
Flint, Michigan, Соединенные Штаты, 48503
- Genesys Hurley Cancer Institute
-
Flint, Michigan, Соединенные Штаты, 48503
- Cancer Hematology Centers - Flint
-
Lansing, Michigan, Соединенные Штаты, 48912
- University of Michigan Health - Sparrow Lansing
-
Livonia, Michigan, Соединенные Штаты, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Macomb, Michigan, Соединенные Штаты, 48044
- Henry Ford Saint John Hospital - Macomb Medical
-
Pontiac, Michigan, Соединенные Штаты, 48341
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Royal Oak, Michigan, Соединенные Штаты, 48073
- Corewell Health William Beaumont University Hospital
-
Troy, Michigan, Соединенные Штаты, 48085
- Corewell Health Beaumont Troy Hospital
-
Ypsilanti, Michigan, Соединенные Штаты, 48197
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
Ypsilanti, Michigan, Соединенные Штаты, 48106
- Huron Gastroenterology PC
-
-
Minnesota
-
Bemidji, Minnesota, Соединенные Штаты, 56601
- Sanford Joe Lueken Cancer Center
-
Coon Rapids, Minnesota, Соединенные Штаты, 55433
- Mercy Hospital
-
Deer River, Minnesota, Соединенные Штаты, 56636
- Essentia Health - Deer River Clinic
-
Duluth, Minnesota, Соединенные Штаты, 55805
- Essentia Health Cancer Center
-
Edina, Minnesota, Соединенные Штаты, 55435
- Fairview Southdale Hospital
-
Hibbing, Minnesota, Соединенные Штаты, 55746
- Essentia Health Hibbing Clinic
-
Maplewood, Minnesota, Соединенные Штаты, 55109
- Saint John's Hospital - Healtheast
-
Minneapolis, Minnesota, Соединенные Штаты, 55407
- Abbott-Northwestern Hospital
-
Rochester, Minnesota, Соединенные Штаты, 55905
- Mayo Clinic in Rochester
-
Saint Louis Park, Minnesota, Соединенные Штаты, 55416
- Park Nicollet Clinic - Saint Louis Park
-
Saint Paul, Minnesota, Соединенные Штаты, 55101
- Regions Hospital
-
Saint Paul, Minnesota, Соединенные Штаты, 55102
- United Hospital
-
Sandstone, Minnesota, Соединенные Штаты, 55072
- Essentia Health Sandstone
-
Virginia, Minnesota, Соединенные Штаты, 55792
- Essentia Health Virginia Clinic
-
-
Mississippi
-
Columbus, Mississippi, Соединенные Штаты, 39705
- Baptist Memorial Hospital and Cancer Center-Golden Triangle
-
Grenada, Mississippi, Соединенные Штаты, 38901
- Baptist Cancer Center-Grenada
-
New Albany, Mississippi, Соединенные Штаты, 38652
- Baptist Memorial Hospital and Cancer Center-Union County
-
Oxford, Mississippi, Соединенные Штаты, 38655
- Baptist Memorial Hospital and Cancer Center-Oxford
-
Southhaven, Mississippi, Соединенные Штаты, 38671
- Baptist Memorial Hospital and Cancer Center-Desoto
-
-
Missouri
-
Cape Girardeau, Missouri, Соединенные Штаты, 63703
- Saint Francis Medical Center
-
City of Saint Peters, Missouri, Соединенные Штаты, 63376
- Siteman Cancer Center at Saint Peters Hospital
-
Creve Coeur, Missouri, Соединенные Штаты, 63141
- Siteman Cancer Center at West County Hospital
-
Farmington, Missouri, Соединенные Штаты, 63640
- Parkland Health Center - Farmington
-
Sainte Genevieve, Missouri, Соединенные Штаты, 63670
- Sainte Genevieve County Memorial Hospital
-
St Louis, Missouri, Соединенные Штаты, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Соединенные Штаты, 63129
- Siteman Cancer Center-South County
-
St Louis, Missouri, Соединенные Штаты, 63136
- Siteman Cancer Center at Christian Hospital
-
St Louis, Missouri, Соединенные Штаты, 63131
- Missouri Baptist Medical Center
-
Sullivan, Missouri, Соединенные Штаты, 63080
- Missouri Baptist Sullivan Hospital
-
-
Montana
-
Anaconda, Montana, Соединенные Штаты, 59711
- Community Hospital of Anaconda
-
Billings, Montana, Соединенные Штаты, 59101
- Billings Clinic Cancer Center
-
Bozeman, Montana, Соединенные Штаты, 59715
- Bozeman Health Deaconess Hospital
-
Great Falls, Montana, Соединенные Штаты, 59405
- Benefis Sletten Cancer Institute
-
Kalispell, Montana, Соединенные Штаты, 59901
- Logan Health Medical Center
-
Missoula, Montana, Соединенные Штаты, 59804
- Community Medical Center
-
-
Nebraska
-
Bellevue, Nebraska, Соединенные Штаты, 68123
- Nebraska Medicine-Bellevue
-
Omaha, Nebraska, Соединенные Штаты, 68198
- University of Nebraska Medical Center
-
Omaha, Nebraska, Соединенные Штаты, 68118
- Nebraska Medicine-Village Pointe
-
-
Nevada
-
Las Vegas, Nevada, Соединенные Штаты, 89102
- OptumCare Cancer Care at Charleston
-
Las Vegas, Nevada, Соединенные Штаты, 89183
- OptumCare Cancer Care at Fort Apache
-
Reno, Nevada, Соединенные Штаты, 89502
- Renown Regional Medical Center
-
-
New Mexico
-
Albuquerque, New Mexico, Соединенные Штаты, 87106
- University of New Mexico Cancer Center
-
-
New York
-
Buffalo, New York, Соединенные Штаты, 14263
- Roswell Park Cancer Institute
-
-
North Dakota
-
Bismarck, North Dakota, Соединенные Штаты, 58501
- Sanford Bismarck Medical Center
-
Fargo, North Dakota, Соединенные Штаты, 58122
- Sanford Roger Maris Cancer Center
-
Fargo, North Dakota, Соединенные Штаты, 58122
- Sanford Broadway Medical Center
-
-
Ohio
-
Centerville, Ohio, Соединенные Штаты, 45459
- Miami Valley Hospital South
-
Dayton, Ohio, Соединенные Штаты, 45409
- Miami Valley Hospital
-
Dayton, Ohio, Соединенные Штаты, 45415
- Miami Valley Hospital North
-
Dayton, Ohio, Соединенные Штаты, 45415
- Dayton Physician LLC - Englewood
-
Dayton, Ohio, Соединенные Штаты, 45409
- Premier Blood and Cancer Center
-
Franklin, Ohio, Соединенные Штаты, 45005-1066
- Atrium Medical Center-Middletown Regional Hospital
-
Greenville, Ohio, Соединенные Штаты, 45331
- Miami Valley Cancer Care and Infusion
-
Kettering, Ohio, Соединенные Штаты, 45429
- Kettering Medical Center
-
Troy, Ohio, Соединенные Штаты, 45373
- Upper Valley Medical Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Соединенные Штаты, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Ontario, Oregon, Соединенные Штаты, 97914
- Saint Alphonsus Cancer Care Center-Ontario
-
-
Pennsylvania
-
Allentown, Pennsylvania, Соединенные Штаты, 18103
- Lehigh Valley Hospital-Cedar Crest
-
Altoona, Pennsylvania, Соединенные Штаты, 16601
- UPMC Altoona
-
Bethlehem, Pennsylvania, Соединенные Штаты, 18017
- Lehigh Valley Hospital - Muhlenberg
-
East Stroudsburg, Pennsylvania, Соединенные Штаты, 18301
- Pocono Medical Center
-
Erie, Pennsylvania, Соединенные Штаты, 16505
- UPMC Hillman Cancer Center Erie
-
Greensburg, Pennsylvania, Соединенные Штаты, 15601
- UPMC Cancer Centers - Arnold Palmer Pavilion
-
Hazleton, Pennsylvania, Соединенные Штаты, 18201
- Lehigh Valley Hospital-Hazleton
-
Mechanicsburg, Pennsylvania, Соединенные Штаты, 17050
- UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion
-
Monroeville, Pennsylvania, Соединенные Штаты, 15146
- UPMC Hillman Cancer Center - Monroeville
-
Pittsburgh, Pennsylvania, Соединенные Штаты, 15232
- UPMC Hillman Cancer Center
-
Pittsburgh, Pennsylvania, Соединенные Штаты, 15237
- UPMC-Passavant Hospital
-
-
South Dakota
-
Sioux Falls, South Dakota, Соединенные Штаты, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
Sioux Falls, South Dakota, Соединенные Штаты, 57104
- Sanford Cancer Center Oncology Clinic
-
-
Tennessee
-
Collierville, Tennessee, Соединенные Штаты, 38017
- Baptist Memorial Hospital and Cancer Center-Collierville
-
Memphis, Tennessee, Соединенные Штаты, 38120
- Baptist Memorial Hospital and Cancer Center-Memphis
-
-
Texas
-
Conroe, Texas, Соединенные Штаты, 77384
- UT MD Anderson - The Woodlands
-
Houston, Texas, Соединенные Штаты, 77030
- UT MD Anderson Cancer Center
-
Houston, Texas, Соединенные Штаты, 77079
- UT MD Anderson - West Houston
-
League City, Texas, Соединенные Штаты, 77573
- UT MD Anderson - League City
-
Sugar Land, Texas, Соединенные Штаты, 77478
- UT MD Anderson - Sugar Land
-
-
Virginia
-
Charlottesville, Virginia, Соединенные Штаты, 22908
- University of Virginia Cancer Center
-
Fairfax, Virginia, Соединенные Штаты, 22031
- Inova Schar Cancer Institute
-
Falls Church, Virginia, Соединенные Штаты, 22042
- Inova Fairfax Hospital
-
Richmond, Virginia, Соединенные Штаты, 23235
- VCU Massey Cancer Center at Stony Point
-
Richmond, Virginia, Соединенные Штаты, 23229
- Virginia Cancer Institute
-
Richmond, Virginia, Соединенные Штаты, 23298
- VCU Massey Comprehensive Cancer Center
-
South Hill, Virginia, Соединенные Штаты, 23970
- VCU Community Memorial Health Center
-
-
Washington
-
Edmonds, Washington, Соединенные Штаты, 98026
- Swedish Cancer Institute-Edmonds
-
Issaquah, Washington, Соединенные Штаты, 98029
- Swedish Cancer Institute-Issaquah
-
Renton, Washington, Соединенные Штаты, 98055
- Valley Medical Center
-
Seattle, Washington, Соединенные Штаты, 98122
- Swedish Medical Center-First Hill
-
-
West Virginia
-
Morgantown, West Virginia, Соединенные Штаты, 26506
- West Virginia University Healthcare
-
-
Wisconsin
-
Appleton, Wisconsin, Соединенные Штаты, 54911
- ThedaCare Regional Cancer Center
-
Ashland, Wisconsin, Соединенные Штаты, 54806
- Duluth Clinic Ashland
-
Berlin, Wisconsin, Соединенные Штаты, 54923
- ThedaCare Cancer Care - Berlin
-
Burlington, Wisconsin, Соединенные Штаты, 53105
- Aurora Cancer Care-Southern Lakes VLCC
-
Cudahy, Wisconsin, Соединенные Штаты, 53110
- Aurora Saint Luke's South Shore
-
Germantown, Wisconsin, Соединенные Штаты, 53022
- Aurora Health Care Germantown Health Center
-
Grafton, Wisconsin, Соединенные Штаты, 53024
- Aurora Cancer Care-Grafton
-
Green Bay, Wisconsin, Соединенные Штаты, 54311
- Aurora BayCare Medical Center
-
Kenosha, Wisconsin, Соединенные Штаты, 53142
- Aurora Cancer Care-Kenosha South
-
Marinette, Wisconsin, Соединенные Штаты, 54143
- Aurora Bay Area Medical Group-Marinette
-
Milwaukee, Wisconsin, Соединенные Штаты, 53209
- Aurora Cancer Care-Milwaukee
-
Milwaukee, Wisconsin, Соединенные Штаты, 53215
- Aurora Saint Luke's Medical Center
-
Milwaukee, Wisconsin, Соединенные Штаты, 53233
- Aurora Sinai Medical Center
-
Neenah, Wisconsin, Соединенные Штаты, 54956
- ThedaCare Regional Medical Center - Neenah
-
Oshkosh, Wisconsin, Соединенные Штаты, 54904
- Vince Lombardi Cancer Clinic - Oshkosh
-
Racine, Wisconsin, Соединенные Штаты, 53406
- Aurora Cancer Care-Racine
-
Sheboygan, Wisconsin, Соединенные Штаты, 53081
- Vince Lombardi Cancer Clinic-Sheboygan
-
Summit, Wisconsin, Соединенные Штаты, 53066
- Aurora Medical Center in Summit
-
Two Rivers, Wisconsin, Соединенные Штаты, 54241
- Vince Lombardi Cancer Clinic-Two Rivers
-
Wauwatosa, Wisconsin, Соединенные Штаты, 53226
- Aurora Cancer Care-Milwaukee West
-
West Allis, Wisconsin, Соединенные Штаты, 53227
- Aurora West Allis Medical Center
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
-
Patient must have enrolled onto EAY191 and must have been given a treatment assignment to ComboMATCH to EAY191-A6 based on the presence of an actionable mutation as defined in EAY191
-
GENERAL COMBOMATCH EAY191:
-
Patients must be registered to the ComboMATCH Registration Protocol (EAY191)
-
Patients must have RAS/RAF/MEK/ERK mutations as determined by the ComboMATCH screening assessment
-
Patients must not have BRAF V600E as determined by the ComboMATCH screening assessment
-
Patients must have disease that can be safely biopsied and agree to a pre-treatment biopsy or have archival tissue available from within 12 months prior to registration on the ComboMATCH Registration Trial (EAY191).
-
Please note the current actionable marker of interest (aMOI)/actionable alteration list for this treatment trial can be found on the Cancer Trials Support Unit (CTSU) website
-
Please note novel/Dynamic aMOI can be submitted for review per the process described in the ComboMATCH Registration Protocol
-
EAY191-A6 REGISTRATION:
-
Participants must have histologically confirmed BTC (intrahepatic cholangiocarcinoma [IHC], extrahepatic cholangiocarcinoma [EHC] or gallbladder cancer [GBC]) that is unresectable or recurrent with a confirmed RAS/RAF/MEK/ERK pathway mutation via any Clinical Laboratory Improvement Act (CLIA)-certified method. BRAFV600E mutations are not eligible due to other ongoing/upcoming studies in this disease cohort
-
Tumor tissue must be available:
-
Adequate archival tumor specimen (obtained within 12 months of EAY191 registration which has not had a Response Evaluation Criteria in Solid Tumors (RECIST) response, complete response (CR) or partial response (PR), to any intervening therapy after collection of the tissue) must be available with formalin-fixed paraffin-embedded tumor tissue (blocks or slides) OR
-
Consent to a new tumor tissue biopsy which is not a representative target lesion. This lesion must be amenable to a minimal risk image-guided or direct vision biopsy
- A new biopsy is preferred but is not required for enrollment in EAY191-A6 if sufficient archival tissue is available as described above.
-
-
Measurable disease per RECIST 1.1 Of note, in the case when a baseline biopsy is done after scans are obtained, a lesion separate from one that is biopsied needs to be measurable per RECIST 1.1. All radiologic studies must be performed within 28 days prior to registration
-
Progression of disease on gemcitabine based first-line regimen (i.e. only one prior line of therapy is permitted)
-
No systemic anti-cancer therapy within 4 weeks of registration to EAY191-A6
-
No prior MEK inhibitor therapy
-
No prior history of treatment with a direct and specific inhibitor of KRAS
-
Patients who only received radio-sensitizing chemotherapy with fluorouracil (5-FU) or capecitabine are eligible, but need to have received and failed first-line systemic chemotherapy upon recurrence. Peri-operative systemic 5-FU/capecitabine and/or oxaliplatin, is allowed if it's been more than 12 months of registration to EAY191-A6
-
No major surgery within 4 weeks (excluding placement of vascular access) of registration to EAY191-A6
-
No minor surgery within 2 weeks of registration to EAY191-A6
-
No palliative radiotherapy within 1 week of registration to EAY191-A6
-
Not pregnant and not nursing, because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown
- Therefore, for women of childbearing potential only, a negative pregnancy test done =< 14 days prior to registration is required
- Adequate contraception is needed for at least 30 days after the last dose of binimetinib and breastfeeding should be discontinued for at least 3 days after the last dose of binimetinib. For FOLFOX regimen, 9 months is recommended for contraception after last dose of oxaliplatin for females of childbearing potential and 6 months for males
-
Age >= 18 years
-
Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
-
Absolute neutrophil count (ANC) >= 1,000/mm^3, no growth factor within 14 days of 1st dose
-
Platelet count >= 75,000/mm^3
-
Creatinine < 1.6 x upper limit of normal (ULN) OR
-
Calculated (Calc.) creatinine clearance >= 50 mL/min, as calculated by the Cockcroft-Gault formula
-
Total bilirubin =< 2.0 x upper limit of normal (ULN); Patients with Gilbert syndrome may enroll if < 3.0 x ULN
-
Aspartate aminotransferase (AST) /alanine aminotransferase (ALT) =< 5.0 x upper limit of normal (ULN)
-
Hemoglobin >= 8 g/dL, no transfusion within 7 days of 1st dose
-
Creatine phosphokinase =< 2.5 x ULN
-
High blood pressure more than 160/90 despite treatment are ineligible
-
No history of interstitial lung disease. No history of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
-
Patients should not have history of bowel perforation or intestinal fistulas in the last 6 months
-
Patients with the inability to swallow oral medications or impaired gastrointestinal absorption due to gastrectomy or active inflammatory bowel disease are ineligible
-
Must have adequate cardiac function with left ventricular ejection fraction >= 50% by echocardiography (ECHO) or multiple-gated acquisition (MUGA) scan. Patients with congenital long QT syndrome are not permitted
-
No history of prolonged QTc or at risk for prolonged QTc due to any reason (for example, concomitant medications during or before chemotherapy that may increase the risk of prolonged QTc), uncontrolled congestive heart failure, prior history of class III/ IV cardiac disease (New York Heart Association [NYHA]), myocardial infarction within the last 6 months, unstable arrhythmias, unstable angina or severe obstructive pulmonary disease
-
No active skin disorder that has required systemic therapy within the past 1 year
-
No history of rhabdomyolysis
-
No concurrent ocular disorders, including:
- Patients with history of glaucoma, history of retinal vein occlusion (RVO), predisposing factors for RVO, including but not limited to uncontrolled hypertension, uncontrolled diabetes
- Patients with history of retinal pathology or evidence of visible retinal pathology that is considered a risk factor for RVO, intraocular pressure > 21 mm Hg as measured by tonometry, or other significant ocular pathology, such as anatomical abnormalities that increase the risk for RVO
- Patients with a history of corneal erosion (instability of corneal epithelium), corneal degeneration, active or recurrent keratitis, and other forms of serious ocular surface inflammatory conditions
- Patients with known or at risk for retinopathies, uveitis or retinal vein occlusion
-
No patients with a history of hypersensitivity to any of the inactive ingredients in binimetinib, nor known severe allergic reactions or hypersensitivity of 5-FU, leucovorin (LV) or oxaliplatin will be allowed to participate in this study for safety concerns
-
No other medical condition (e.g. cardiac, gastrointestinal, pulmonary, psychiatric, neurological, genetic, etc.) that in the opinion of the investigator would places the subject at unacceptably high risk for toxicity
-
No prior allogeneic stem cell or solid organ transplantation
-
Central nervous system (CNS) metastases must have been treated with local therapy (surgery, radiation, ablation) with systemic steroids tapered to a physiologic dose (10 mg or prednisone equivalent or less)
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
-
Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
-
Patients must not have grade 2 neuropathy or greater, within 14 days prior to registration
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Активный компаратор: Arm 1 (mFOLFOX6)
Patients receive leucovorin IV over 2 hours and oxaliplatin IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1-2. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients undergo collection of blood during screening and on study, and undergo CT with contrast, MRI, or FDG-PET throughout the trial as clinically indicated. Patients may also undergo bone scans on study and may undergo biopsies throughout the study as clinically indicated. |
Given IV
Другие имена:
Undergo CT
Другие имена:
Undergo MRI
Другие имена:
Undergo biopsy
Другие имена:
Undergo collection of blood
Другие имена:
Given IV
Другие имена:
Given IV
Другие имена:
Undergo bone scan
Другие имена:
|
|
Экспериментальный: Arm 2 (binimetinib, mFOLFOX6)
Patients receive binimetinib PO on days 1-14, and leucovorin IV, oxaliplatin IV, and fluorouracil IV as in Arm 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA and collection of blood during screening and on study, and undergo CT with contrast, MRI, or FDG-PET throughout the trial as clinically indicated. Patients may also undergo bone scans on study and may undergo biopsies throughout the study as clinically indicated. |
Given IV
Другие имена:
Undergo CT
Другие имена:
Undergo MRI
Другие имена:
Undergo ECHO
Другие имена:
Undergo MUGA
Другие имена:
Undergo biopsy
Другие имена:
Undergo collection of blood
Другие имена:
Given PO
Другие имена:
Given IV
Другие имена:
Given IV
Другие имена:
Undergo bone scan
Другие имена:
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Overall survival (OS)
Временное ограничение: From randomization to the time of death due to any cause, assessed up to 30 months
|
The primary efficacy analysis will be to compare the OS distributions between those treated with modified leucovorin, fluorouracil and oxaliplatin (mFOLFOX6) and binimetinib versus (vs.) mFOLFOX6. Despite being a randomized phase II trial, we will utilize an intent to treat approach such that patients will be analyzed based on the treatment arm to which they were randomized. As defined above, OS will be compared between the two treatment arms using Kaplan-Meier methods. The hazard ratio, median OS, and estimated OS rates at 6, 12, 18, 24, and 30 months will be estimated along with corresponding 95% confidence intervals. Anticipating that the treatment arms will be balanced in terms of the potential confounders reflect in the stratification factors, a log-rank test will be used to compare the OS distributions between the two treatment arms in this cohort. |
From randomization to the time of death due to any cause, assessed up to 30 months
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Objective response
Временное ограничение: Up to 5 years
|
Objective response by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 criteria will be estimated using objective response rate (ORR) where ORR is defined as the number of evaluable patients achieving a response (partial response [PR] or complete response [CR] per RECIST v1.1) during treatment with study therapy divided by the total number of evaluable patients. Rates of response will be compared across arms using a Chi-Square Test for Proportion. Point estimates will be generated for objective response rates within each arm along with 95% confidence intervals using the Clopper-Pearson method. |
Up to 5 years
|
|
Progression free survival (PFS)
Временное ограничение: From study entry to the first of either disease progression or death from any cause, assessed up to 5 years
|
Disease progression will be determined based on RECIST 1.1 criteria. PFS will be estimated using the Kaplan-Meier method. The median PFS and 95% confidence interval will be reported. Patients will be censored at the last disease assessment date. |
From study entry to the first of either disease progression or death from any cause, assessed up to 5 years
|
|
Duration of response (DoR)
Временное ограничение: Up to 5 years
|
Defined for all evaluable patients who have achieved an objective response as the date at which the patient's earliest best objective status is first noted to be either a CR or PR to the earliest date progression is documented, or death if no prior evidence of disease progression. The distribution of DoR will be estimated using the method of Kaplan-Meier. |
Up to 5 years
|
|
Clinical benefit
Временное ограничение: Up to 5 years
|
Defined as achieving CR, PR, or stable disease (SD) for at least 4 months while on treatment. Disease status will be assessed using RECIST v. 1.1 criteria. Clinical benefit rate (CBR) will be calculated as the proportion of evaluable patients who achieve clinical benefit. The final CBR point estimate and corresponding 95% confidence interval calculated using Clopper-Pearson method. |
Up to 5 years
|
|
Incidence of adverse events
Временное ограничение: Up to 5 years
|
Patients will be evaluated for adverse events using the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events version 5.0. Summary statistics (e.g., mean, median, standard deviation) and frequency tables will be used to describe the distributions of adverse events. Rates of adverse events occurring in the treatment arm will be compared to the control arm with chi-squared tests (or suitable alternative) used for comparisons where applicable. Tolerability will also be evaluated, summarizing rates of dose delays or modifications, reasons patients end treatment, and time to end of active treatment. |
Up to 5 years
|
Другие показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Prognostic model/scoring system
Временное ограничение: Up to 5 years
|
Defined as presence of peritoneal disease/locally advanced disease/metastatic disease, Eastern Cooperative Oncology Group (ECOG) performance status, CA19.9 level. Will fit multivariate Cox regression models including MAPK mutation status, presence of peritoneal disease/locally advance disease/metastatic disease, ECOG performance status, and CA19-9 level, stratified by treatment arm. We will calculate C-statistics with 5-fold cross-validation |
Up to 5 years
|
|
Albumin
Временное ограничение: Up to 5 years
|
Will correlate outcome with albumin. |
Up to 5 years
|
|
Presence of MAPK pathway mutations
Временное ограничение: Up to 5 years
|
Will correlate with activity of addition of binimetinib therapy to standard 2nd line chemotherapy. |
Up to 5 years
|
|
Activity of addition of binimetinib therapy to standard 2nd line chemotherapy
Временное ограничение: Up to 5 years
|
Will correlate with presence of MAPK pathway mutations. |
Up to 5 years
|
|
Whole-exome sequencing and ribonucleic acid (RNA)-sequencing
Временное ограничение: Up to 5 years
|
Will be used to assess determinants of response and resistance. Concordance of diagnostic tumor mutation profile generated by the Designated Laboratory, the pre-treatment biopsy mutation profile, and the pre-treatment circulating tumor deoxyribonucleic acid (ctDNA) mutation profile will be assessed. Details are provided in the statistical plan of the ComboMATCH Registration Protocol. |
Up to 5 years
|
|
Changes in plasma MAPK mutations allelic burden and other molecular findings
Временное ограничение: Up to 5 years
|
Will correlate changes with clinical activity, disease course as well as response/resistance to therapy. |
Up to 5 years
|
|
Detection of mutations as well as prediction of outcomes
Временное ограничение: Up to 5 years
|
Will evaluate if our machine learning algorithm for RAS/RAF/MEK/ERK pathway mutations correlates with detection of mutations as well as prediction of outcomes from samples obtained in this study. |
Up to 5 years
|
Соавторы и исследователи
Спонсор
Следователи
- Главный следователь: Ardaman Shergill, Alliance for Clinical Trials in Oncology
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Действительный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
- Новообразования по локализации
- Новообразования
- Новообразования по гистологическому типу
- Новообразования пищеварительной системы
- Заболевания пищеварительной системы
- Заболевания желчевыводящих путей
- Новообразования железистые и эпителиальные
- Аденокарцинома
- Карцинома
- Заболевания желчного пузыря
- Новообразования желчевыводящих путей
- Холангиокарцинома
- Клацкин опухоль
- Новообразования желчного пузыря
- Органические химические вещества
- Гетероциклические соединения, 1-кольцо
- Гетероциклические соединения
- Гетероциклические соединения, 2-кольцо
- Гетероциклические соединения, слитое кольцо
- Следственные методы
- Клинические лабораторные методы
- Диагностические методы и процедуры
- Диагноз
- Хирургические процедуры, оперативные
- Цитологические методы
- Цитодиагностика
- Ферменты и коэнзименты
- Координационные комплексы
- Пиримидины
- Диагностические методы, хирургический
- Химические методы, аналитические
- Анализ спектра
- Формилтетрагидрофолаты
- Тетрагидрофолаты
- Фолиевая кислота
- Птерины
- Птеридины
- Урацил
- Пиримидиноны
- Коэнзименты
- Оксалиплатин
- Фторурацил
- Лейковорин
- Биопсия
- Обработка образца
- Магнитно -резонансная спектроскопия
- биниметиниб
- Dehydroftorafur
Другие идентификационные номера исследования
- NCI-2022-07833
- U10CA180821 (Грант/контракт NIH США)
- NCI-2022-07833 (Идентификатор реестра: CTRP (Clinical Trial Reporting Program))
- EAY191-A6 (Другой идентификатор: CTEP)
- EAY191-A6 (Другой идентификатор: Alliance for Clinical Trials in Oncology)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
продукт, произведенный в США и экспортированный из США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .